MedTrace Logo

Quadratus Lumborum Block Versus Thoracic Paravertebral Block

NCT04827043 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-04-01

No results posted yet for this study

Summary

This study is to assess and compare the analgesic efficacy and safety of quadratus lumbotum block and paravertebral block in gynacological cancer patients.

Conditions

  • Postoperative Analgesia

Interventions

COMBINATION_PRODUCT

Ultrasound guided quadratus lumborum block

prospective randomized comparative study between Group (1) : quadratus lumborum block

COMBINATION_PRODUCT

Ultrasound guided thoracic paravertebral block

PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Khaled A El-samahy, Professor · National Cancer Institute (NCI)

  • Ekramy M Abd-elghaffar, MD · National Cancer Institute (NCI)

  • Esam Ab Mahran, MD · National Cancer Institute (NCI)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-07-30
Completion
2021-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827043 on ClinicalTrials.gov